MX2022001013A - Degradador selectivo del receptor de estrogeno. - Google Patents

Degradador selectivo del receptor de estrogeno.

Info

Publication number
MX2022001013A
MX2022001013A MX2022001013A MX2022001013A MX2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
enyl
Prior art date
Application number
MX2022001013A
Other languages
English (en)
Spanish (es)
Inventor
Jayraj Dilipbhai Aradhye
Bhavesh Mohanbhai Panchal
Biswajit Samanta
Ranjan Kumar Pal
Trinadha Rao Chitturi
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2022001013A publication Critical patent/MX2022001013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022001013A 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno. MX2022001013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
MX2022001013A true MX2022001013A (es) 2022-02-22

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001013A MX2022001013A (es) 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno.

Country Status (15)

Country Link
US (2) US11014915B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003525A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541938A (cg-RX-API-DMAC7.html)
KR (1) KR20220046586A (cg-RX-API-DMAC7.html)
CN (1) CN114302879A (cg-RX-API-DMAC7.html)
AU (1) AU2020317099A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148592A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000156A1 (cg-RX-API-DMAC7.html)
IL (1) IL290036A (cg-RX-API-DMAC7.html)
MX (1) MX2022001013A (cg-RX-API-DMAC7.html)
PE (1) PE20221588A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201157B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) * 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12391667B2 (en) 2019-07-22 2025-08-19 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
US10865199B2 (en) * 2015-10-27 2020-12-15 Sun Pharma Advanced Research Company Limited Heterocyclic antiestrogens
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
US20210261534A1 (en) 2021-08-26
KR20220046586A (ko) 2022-04-14
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CN114302879A (zh) 2022-04-08
AU2020317099A1 (en) 2022-02-24
PH12022550182A1 (en) 2022-11-14
US11014915B2 (en) 2021-05-25
EP4003525A1 (en) 2022-06-01
CL2022000156A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CL2022000156A1 (es) Degradador selectivo del receptor de estrógeno
MX2021009569A (es) Procesos y compuestos.
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
PH12021550296A1 (en) Substituted indoles and methods of use thereof
MX2023010043A (es) Moduladores del receptor de androgenos y metodos para su uso.
EP3773552A4 (en) COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
UY30292A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico
EA201690328A1 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
UY32352A (es) Régimen de dosificación para un agonista de los receptores de s1p
EP4212532A3 (en) Mitragynine analogs and uses thereof
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
ZA202301275B (en) Indole compounds as androgen receptor modulators
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
PH12014501157A1 (en) Pharmaceutical formulations
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CL2019003249A1 (es) Protocolo mejorado para el tratamiento de nefritis lúpica.
CR10540A (es) Derivados ciclopropil amina
WO2019123482A8 (en) Pharmaceutical composition for the treatment of cancer
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
UY33722A (es) Oxazolidinonas como moduladores de mglur5
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
EA201691133A1 (ru) (r)-3-((3s,4s)-3-фтор-4-(4-гидроксифенил)пиперидин-1-ил)-1-(4-метилбензил)пирролидин-2-он и его пролекарственные средства для лечения психиатрических нарушений